ExodusPoint Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

ExodusPoint Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,817	Closed	-$46K	–	1448
2024 Q4	$46K	Sell	13,817 -1,926	-12%	-$6.4K	﹤0.01%	1428
2024 Q3	$53K	Sell	15,743 -1,817	-10%	-$6.59K	﹤0.01%	1537
2024 Q2	$58K	Hold	17,560	–	–	﹤0.01%	1443
2024 Q1	$71K	Buy	17,560 +798	+5%	+$3.12K	﹤0.01%	1429
2023 Q4	$51K	Sell	16,762 -12,092	-42%	-$36.6K	﹤0.01%	1381
2023 Q3	$87K	Sell	28,854 -13,381	-32%	-$45.5K	﹤0.01%	1591
2023 Q2	$158K	Buy	+42,235	New	+$158K	﹤0.01%	1710
2022 Q4	–	Sell	-11,293	Closed	-$64K	–	1628
2022 Q3	$64K	Sell	11,293 -434	-4%	-$3.32K	﹤0.01%	1785
2022 Q2	$83K	Buy	+11,727	New	+$80.1K	﹤0.01%	1760
2022 Q1	–	Sell	-23,959	Closed	-$214K	–	2183
2021 Q4	$214K	Buy	+23,959	New	+$373K	﹤0.01%	1799

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ExodusPoint Capital Management's AVIR Position: Q1 2025 in Review

ExodusPoint Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 13,817 shares — an estimated $46K sold.

ExodusPoint Capital Management first reported a position in AVIR in Q4 2021 and held it in 10 quarters. The position peaked at $214K in Q4 2021. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

ExodusPoint Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 13,817 Atea Pharmaceuticals shares in Q1 2025, an estimated $46K.
ExodusPoint Capital Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 10 quarters.
ExodusPoint Capital Management's Atea Pharmaceuticals position peaked at $214K in Q4 2021.
103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.